European Biotech Acquisition (EBACU) Short Interest Ratio & Short Volume

Short interest is the volume of European Biotech Acquisition shares that have been sold short but have not yet been covered or closed out. As of September 15th, investors have sold 11,800 shares of EBACU short. 0.09% of European Biotech Acquisition's shares are currently sold short. Learn More on European Biotech Acquisition's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EBACU shares currently have a short interest ratio of 4.0. Learn More on European Biotech Acquisition's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.09% of European Biotech Acquisition's floating shares are currently sold short.

European Biotech Acquisition saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 11,800 shares, an increase of 168.2% from the previous total of 4,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

European Biotech Acquisition currently has issued a total of 0 shares. Some of European Biotech Acquisition's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. European Biotech Acquisition currently has a public float of 12,750,000 shares.

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($4.11 billion), Canadian Natural Resources Limited ($3.64 billion), Charter Communications, Inc. ($3.15 billion), Lucid Group, Inc. ($2.09 billion), Chesapeake Energy Co. ($2.02 billion), Coinbase Global, Inc. ($2.01 billion), T. Rowe Price Group, Inc. ($1.92 billion), Plug Power Inc. ($1.77 billion), Rivian Automotive, Inc. ($1.71 billion), and Williams-Sonoma, Inc. ($1.59 billion). View all of the most shorted stocks.

Short selling EBACU is an investing strategy that aims to generate trading profit from European Biotech Acquisition as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for European Biotech Acquisition occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EBACU, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EBACU, twice per month. The most recent reporting period available is September, 15 2022.